Press Room

AAPS 2015

Start
Sunday, October 25, 2015 - 00:00
End
Thursday, October 29, 2015 - 23:00
Location: Orlando, USA
Booth Number: 1845

HOVIONE'S PRESENTATION

Screening Methodologies for the Development of Spray-Dried Amorphous Solid Dispersions
Speaker: Marcio Temtem (Oral Drug Forms Group Leader)
Date: Tuesday, October 27, 2015
Time: 10:00 AM – 12:00 PM, OCCC - Room W310
This presentation will take place during the Roundtable Session "What a Guess! - How to Predict Which Polymer is the One for My Amorphous Solids Dispersion"

Expanding in the Right Direction
Speaker: Antonio Dinis (Director, Marketing & Communication)
Date: Tuesday, October 27 
Time: 10:25 AM - 10:40 AM, OCCC - End of 200 Aisle
Having Hovione’s expansion plans as a starting point we will explore how why capacity alone is not what make the company the leader in pharmaceutical spray drying. Development by Design cases studies will be presented to illustrate how Hovione is making strides to the third evolutionary stage of the industry.

 

Poster Session at AAPS:  

Evaporation of binary mixtures and shell formation in spray dried droplets
Pedro Valente

A Direct Approach for Spray Drying Process Development: From Laboratory to Commercial Scale
Rui Ferreira

Benchmarking the Bioperformance of Amorphous Solid Dispersions Produced by Spray Drying and a Solvent Controlled Precipitation Process
Iris Duarte

Predicting the performance of amorphous solid dispersions based on molecular descriptors and statistical analysis
Iris Duarte

Production of Co-crystals: Microfluidization vs High Shear Mixing Assisted Process
Tiago Profirio

Achieving High Efficiency Taste Masking with Particle Engineering
Inês Matos

Loss of Compactability in Roller Compaction—Influencing Parameters and Analytical Characterization
João Henriques

Analytical Qbd Model: a new stepwise methodology for analytical chemistry
Lúcia Volta e Sousa1,2, António Ramos1, Rui Loureiro1, José C. Menezes2
1 Hovione Farmaciência S.A.
2 Institute for Biotechnology and Biosciences, Instituto Superior Técnico, Universidade de Lisboa

 

 

Also in the Press Room

See All

Continuous Tableting (CT) is defined as continuous manufacturing of oral dose drugs, specifically tablets. As per ICH's Q13 definition1, a continuous manufacturing process in the pharmaceutical industry comprises at least two unit operations integrated from a mechanical and software perspective. There is a wide combination of possible CT process configurations that are dependent on the needs of the intended product formulation and each of the individual unit operations that constitute the process train can be continuous, semi-continuous, or batch processes. The typical manufacturing processes for tablet formulation are direct compression (DC), dry granulation (DG) and wet granulation (WG)2 - details on these manufacturing processes are beyond the scope of this article, so the interested reader is directed to relevant literature. The actual implementation of CT technology in a facility can broadly vary depending on the level of desired integration and automation. Process trains can be designed to be flexible and converted between multiple configurations (e.g. continuous DC, DG and WG), controlled by the end user from one single software and within a single clean room. The other possibility would be for subsections of the CT process to be divided into multiple clean rooms where inprocess materials are transferred between suites via a bin-to-bin approach (e.g. a granulation suite to prepare granules from raw materials followed by continuous DC (CDC) to blend the granules and produce tablets). The level of automation and instrumentation designed into the CT process (typically involving Process Analytical Technologies, PAT) can open the possibility to implement sophisticated control strategies. Key components of a control strategy that need to be considered for CT are material tracking and genealogy, knowledge of the residence time distribution (RTD), and in-process controls (spectroscopic and/or soft sensors based on process parameters). Holistically, these control strategy elements enable the implementation of a material diversion strategy to automatically divert out of specification material from the process. In their most advanced form, control strategies may also enable real time release testing (RTRt) of the final tablet drug product and reduce the off-line analytical burden and the number of operators needed to manage the process.   Read the full article at gmp-journal.com  

Article

Continuous Tableting and the Road to Global Adoption

Mar 04, 2024